1. Home
  2. SOS vs BIVI Comparison

SOS vs BIVI Comparison

Compare SOS & BIVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOS Limited

SOS

SOS Limited

HOLD

Current Price

$1.30

Market Cap

10.7M

Sector

Finance

ML Signal

HOLD

Logo BioVie Inc.

BIVI

BioVie Inc.

HOLD

Current Price

$1.27

Market Cap

8.5M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOS
BIVI
Founded
2004
2013
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
8.5M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SOS
BIVI
Price
$1.30
$1.27
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
19.1K
107.8K
Earning Date
09-26-2025
02-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$260,505,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
134.43
N/A
52 Week Low
$1.02
$1.06
52 Week High
$9.62
$18.75

Technical Indicators

Market Signals
Indicator
SOS
BIVI
Relative Strength Index (RSI) 40.57 54.12
Support Level $1.26 $1.08
Resistance Level $1.57 $1.21
Average True Range (ATR) 0.16 0.10
MACD -0.03 0.01
Stochastic Oscillator 16.67 91.30

Price Performance

Historical Comparison
SOS
BIVI

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.

About BIVI BioVie Inc.

BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.

Share on Social Networks: